BeOne Medicines Q3 2026 net income more than triples to $384.71 million
ONC•BeOne Medicines’ third-quarter GAAP net income more than tripled to $384.71 million, while revenue rose 34% to $1.89 billion. The company raised its FY26 revenue guidance to $6.9 billion-$7 billion and GAAP operating income outlook to $1.2 billion-$1.3 billion.
1. Quarterly results
BeOne Medicines’ third-quarter 2026 GAAP net income more than tripled year over year to $384.71 million. Revenue increased 34% to $1.89 billion, and BRUKINSA revenue rose 34% to $1.4 billion.
2. Trial and guidance
Tacabrutideg’s pivotal Phase 2 trial met its primary endpoint of overall response rate in relapsed/refractory chronic lymphocytic leukemia. BeOne Medicines raised its FY26 revenue guidance to $6.9 billion-$7 billion and its GAAP operating income outlook to $1.2 billion-$1.3 billion.
